Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomer M Mark

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2015
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell TransplantationMichael J Satlin, Santosh Vardhana, Rosemary Soave, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2013
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myelomaTomer M Mark, Whitney Reid, Ruben Niesvizky, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 <sup>CRBN</sup> to Enhance Immunomodulatory Drug Therapy in Multiple MyelomaXiangao Huang, David Jayabalan, Maurizio Di Liberto, et al.
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Cancer Research Communications|December 19, 2024
Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene ExpressionDenis Ohlstrom, Zachary J Walker, Abhishek Pandey, et al.
Cancers|November 25, 2023
CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived XenograftsMichael J VanWyngarden, Zachary J Walker, Yang Su, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two PracticesAmrita D Singh, Sapna Parmar, Khilna Patel, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Blood Advances|April 21, 2020
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progressionZachary J Walker, Michael J VanWyngarden, Brett M Stevens, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2015
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell TransplantationMichael J Satlin, Santosh Vardhana, Rosemary Soave, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2013
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myelomaTomer M Mark, Whitney Reid, Ruben Niesvizky, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 <sup>CRBN</sup> to Enhance Immunomodulatory Drug Therapy in Multiple MyelomaXiangao Huang, David Jayabalan, Maurizio Di Liberto, et al.
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Cancer Research Communications|December 19, 2024
Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene ExpressionDenis Ohlstrom, Zachary J Walker, Abhishek Pandey, et al.
Cancers|November 25, 2023
CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived XenograftsMichael J VanWyngarden, Zachary J Walker, Yang Su, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive PatientsScott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two PracticesAmrita D Singh, Sapna Parmar, Khilna Patel, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Blood Advances|April 21, 2020
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progressionZachary J Walker, Michael J VanWyngarden, Brett M Stevens, et al.
Pageof 5